Lonza GroupSTU:LO3 +1.43%83 Buyback Yield % is 1.26 as of Jul. 05, 2026, which is 152% above its 10-year median of 0.50. GuruFocus rates STU:LO3 with a GF Score™ of 83/100 and a GF Value™ of €645.09 (Fairly Valued). The stock has 4 warning signs investors should review. Among 90 Medical Diagnostics & Research companies, Lonza Group ranks better than 72.22% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Lonza Group's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:LO3 vs TMO, DHR, IDXX: Buyback Yield % Comparison
For the Diagnostics & Research subindustry, Lonza Group's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lonza Group Buyback Yield % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Lonza Group's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Lonza Group's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lonza Group (STU:LO3) has a Buyback Yield % of 1.26 as of Jul. 05, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lonza Group and its competitors. This is 152% above median its historical median of 0.50. According to the industry distribution chart, Lonza Group ranks #25 out of 90 companies in the Medical Diagnostics & Research industry, placing it in the top 27.8%.
Is Lonza Group's Buyback Yield % too high?
Lonza Group's current Buyback Yield % of 1.26 is 152% above median its 10-year median of 0.50. Based on the distribution chart, Lonza Group ranks #25 out of 90 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Lonza Group has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Lonza Group's Buyback Yield % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Lonza Group ranks #25 out of 90 companies for Buyback Yield %. This puts Lonza Group in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Diagnostics & Research company?
A good Buyback Yield % depends on the Medical Diagnostics & Research industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Lonza Group and its competitors. Lonza Group's current Buyback Yield % is 1.26, which is 152% above median its own 10-year median of 0.50. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lonza Group stock overvalued right now?
Based on GuruFocus' analysis, Lonza Group (STU:LO3) is currently considered Fairly Valued. The stock's GF Value™ is €645.09, compared to a current price of €623.60 — trading 3.3% below its estimated fair value. The current Buyback Yield % is 1.26, which is 152% above median its 10-year median of 0.50. Lonza Group's overall GF Score™ is 83/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Lonza Group (STU:LO3), the current Buyback Yield % is 1.26 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lonza Group (STU:LO3) Overvalued in 2026?
Based on GuruFocus' analysis, Lonza Group stock appears to be undervalued.
The current stock price of €623.60 is trading 3.3% below its estimated GF Value™ of €645.09.
GuruFocus considers Lonza Group to be Fairly Valued.
Key valuation signals for STU:LO3:
Buyback Yield %: 1.26 (152% above median its 10-year median of 0.50)
GF Value™: €645.09 vs. price of €623.60 (3.3% below fair value)
No single metric tells the full story. See the STU:LO3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lonza Group is a contract development and manufacturing organization. It operates under four segments: small molecules, biologics, cell and gene, and capsules and health ingredients. Lonza derives its revenue primarily from long-term supply agreements with pharmaceutical customers. The company provides development and manufacturing services throughout the entire lifecycle of a product, from drug research to commercial supply. The majority of Lonza's customers are pharmaceutical and biotechnology companies, academic institutions, and government research organizations.
83GF Score
Get the complete analysis for STU:LO3
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LO3 has been successfully added to your 
